EP2509620A4 - NANOPARTICLE CARRIER SYSTEM BASED ON HUMAN SERUM ALBUMIN FOR PHOTODYNAMIC THERAPIES - Google Patents

NANOPARTICLE CARRIER SYSTEM BASED ON HUMAN SERUM ALBUMIN FOR PHOTODYNAMIC THERAPIES

Info

Publication number
EP2509620A4
EP2509620A4 EP10836582.6A EP10836582A EP2509620A4 EP 2509620 A4 EP2509620 A4 EP 2509620A4 EP 10836582 A EP10836582 A EP 10836582A EP 2509620 A4 EP2509620 A4 EP 2509620A4
Authority
EP
European Patent Office
Prior art keywords
albuminum
nanoparticles
human serum
photodynamic therapy
transportation systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP10836582.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2509620A2 (en
Inventor
Klaus Langer
Matthias Wacker
Beate Röder
Annegret Pruess
Volker Albrecht
Susanna Gräfe
Arno Wiehe
Briesen Hagen Von
Sylvia Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolitec Holding & Co Kg GmbH
Original Assignee
BIOLITEC PHARMA IP & INVESTMENT Ltd
BIOLITEC PHARMA IP & INVEST Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOLITEC PHARMA IP & INVESTMENT Ltd, BIOLITEC PHARMA IP & INVEST Ltd filed Critical BIOLITEC PHARMA IP & INVESTMENT Ltd
Publication of EP2509620A2 publication Critical patent/EP2509620A2/en
Publication of EP2509620A4 publication Critical patent/EP2509620A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10836582.6A 2009-12-11 2010-12-08 NANOPARTICLE CARRIER SYSTEM BASED ON HUMAN SERUM ALBUMIN FOR PHOTODYNAMIC THERAPIES Pending EP2509620A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28590209P 2009-12-11 2009-12-11
US12/941,350 US9211283B2 (en) 2009-12-11 2010-11-08 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
PCT/US2010/059364 WO2011071968A2 (en) 2009-12-11 2010-12-08 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy

Publications (2)

Publication Number Publication Date
EP2509620A2 EP2509620A2 (en) 2012-10-17
EP2509620A4 true EP2509620A4 (en) 2015-10-21

Family

ID=44143223

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10836582.6A Pending EP2509620A4 (en) 2009-12-11 2010-12-08 NANOPARTICLE CARRIER SYSTEM BASED ON HUMAN SERUM ALBUMIN FOR PHOTODYNAMIC THERAPIES

Country Status (7)

Country Link
US (1) US9211283B2 (enExample)
EP (1) EP2509620A4 (enExample)
JP (1) JP5972171B2 (enExample)
CN (1) CN102740875A (enExample)
BR (1) BR112012013952A2 (enExample)
CA (1) CA2784001C (enExample)
WO (1) WO2011071968A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2591803A1 (de) 2011-11-09 2013-05-15 APOCARE Pharma GmbH Zusammensetzung für die photodynamische Diagnostik und Therapie von Tumoren
CN103169968B (zh) * 2013-03-12 2014-11-26 中国科学院理化技术研究所 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用
KR101329646B1 (ko) * 2013-05-02 2013-11-14 주식회사 지니스 표적지향증폭형 항암나노입자 및 이의 제조방법
EP3201201B1 (en) 2014-09-30 2022-01-26 biolitec unternehmensbeteiligungs II AG Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
CN104587466B (zh) * 2014-12-15 2017-11-21 苏州大学 蛋白‑聚吡咯复合物及蛋白‑聚吡咯复合物衍生物的制备方法与应用
ES3011714T3 (en) 2016-02-26 2025-04-08 Biolitec Holding Gmbh & Co Kg Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
DE102016125666A1 (de) * 2016-12-23 2018-06-28 Michael Denck HSA-Galenik
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
US20220025185A1 (en) 2018-12-10 2022-01-27 Universitat Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
WO2020242552A1 (en) 2019-03-14 2020-12-03 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
CN110251672B (zh) * 2019-06-18 2022-04-01 深圳大学 一种纳米诊疗剂及其制备方法与应用
CN111110861B (zh) * 2020-02-23 2023-08-25 上海交通大学医学院附属瑞金医院 一种基于人血清白蛋白的载药颗粒及其制备方法
CN112972676B (zh) * 2020-08-17 2024-09-24 滨州医学院 HSA-Biotin-DDA-TCPP分子的合成及其作为光动力治疗剂及纳米药的应用
CN113855645B (zh) * 2021-09-13 2024-02-02 苏州大学 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用
WO2023039691A1 (zh) * 2021-09-17 2023-03-23 苏州大学 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129337A2 (en) * 2009-04-28 2010-11-11 Ceramoptec Industries, Inc. New oral formulations for tetrapyrrole derivatives

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9420355D0 (en) * 1994-10-10 1994-11-23 Univ Nottingham Preparation of protein microspheres, films and coatings
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
WO2000061584A1 (en) 1999-04-14 2000-10-19 The University Of British Columbia IMPROVED β,β,-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, AND BACTERIOCHLORINS
AU7599900A (en) 1999-09-23 2001-04-24 Dabur Research Foundation Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles
CA2449828A1 (en) * 2001-06-04 2003-01-16 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
US7455858B2 (en) * 2002-05-16 2008-11-25 Qlt Inc. Compositions and methods for delivery of photosensitive drugs
US8709449B2 (en) * 2004-02-12 2014-04-29 Biolitec Pharma Marketing Ltd Methods and compositions for improving photodynamic therapy through administration of lipids
DE102004011776A1 (de) * 2004-03-09 2005-11-03 Lts Lohmann Therapie-Systeme Ag Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen
JP2006056807A (ja) * 2004-08-18 2006-03-02 Konica Minolta Medical & Graphic Inc 光線力学療法製剤
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
US20090304803A1 (en) * 2005-06-06 2009-12-10 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
KR20100133475A (ko) * 2008-04-10 2010-12-21 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 그의 용도
US8229064B2 (en) * 2009-04-30 2012-07-24 Thermo Scientific Portable Analytical Instruments Inc. Localization of an element of interest by XRF analysis of different inspection volumes
US20110275686A1 (en) * 2009-12-11 2011-11-10 Biolitec, Inc. Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129337A2 (en) * 2009-04-28 2010-11-11 Ceramoptec Industries, Inc. New oral formulations for tetrapyrrole derivatives

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ANHORN M G ET AL: "Freeze drying of human serum albumin (HSA) nanoparticles with different excipients", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 363, no. 1-2, 3 November 2008 (2008-11-03), pages 162 - 169, XP025431308, ISSN: 0378-5173, [retrieved on 20080715], DOI: 10.1016/J.IJPHARM.2008.07.004 *
BOURDON O ET AL: "A comparative study of the cellular uptake, localization and phototoxicity of meta-tetra(hydroxyphenyl) chlorin encapsulated in surface-modified submicronic oil/water carriers in HT29 tumor cells", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, ELSEVIER SCIENCE S.A., BASEL, CH, vol. 55, no. 2-3, 1 April 2000 (2000-04-01), pages 164 - 171, XP002522470, ISSN: 1011-1344, DOI: 10.1016/S1011-1344(00)00043-9 *
CHATTERJEE D K ET AL: "Nanoparticles in photodynamic therapy: An emerging paradigm", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 60, no. 15, 14 December 2008 (2008-12-14), pages 1627 - 1637, XP025656957, ISSN: 0169-409X, [retrieved on 20080920], DOI: 10.1016/J.ADDR.2008.08.003 *
CHEN K ET AL: "Novel photosensitizer-protein nanoparticles for Photodynamic therapy: Photophysical characterization and in vitro investigations", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, ELSEVIER SCIENCE S.A., BASEL, CH, vol. 96, no. 1, 17 July 2009 (2009-07-17), pages 66 - 74, XP026145049, ISSN: 1011-1344, [retrieved on 20090422], DOI: 10.1016/J.JPHOTOBIOL.2009.04.006 *
CHIARA COMPAGNIN ET AL: "The cellular uptake of meta-tetra(hydroxyphenyl)chlorin entrapped in organically modified silica nanoparticles is mediated by serum proteins", NANOTECHNOLOGY, IOP, BRISTOL, GB, vol. 20, no. 34, 26 August 2009 (2009-08-26), pages 345101, XP020160823, ISSN: 0957-4484 *
K. LANGER ET AL: "Optimization of the preparation process for human serum albumin (HSA) nanoparticles", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 257, no. 1-2, May 2003 (2003-05-01), pages 169 - 180, XP055211340, ISSN: 0378-5173, DOI: 10.1016/S0378-5173(03)00134-0 *
KONAN Y N ET AL: "ENCAPSULATION OF P-THPP INTO NANOPARTICLES: CELLULAR UPTAKE, SUBCELLULAR LOCALIZATION AND EFFECT OF SERUM ON PHOTODYNAMIC ACTIVITY", PHOTOCHEMISTRY AND PHOTOBIOLOGY, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 77, no. 6, 2003, pages 638 - 644, XP008022464, ISSN: 0031-8655, DOI: 10.1562/0031-8655(2003)077<0638:EOPINC>2.0.CO;2 *
KONAN Y N ET AL: "Preparation and characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 55, no. 1, 2003, pages 115 - 124, XP004404966, ISSN: 0939-6411, DOI: 10.1016/S0939-6411(02)00128-5 *
KRUEGER THORSTEN ET AL: "Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC.", LASERS IN SURGERY AND MEDICINE 2003, vol. 32, no. 1, 2003, pages 61 - 68, XP055683050, ISSN: 0196-8092, DOI: 10.1002/lsm.10113 *
SAGHATOLESLAMI: "Preparation and Characterization of Protein Nanoparticles from Human Serum Albumin (HSA) as a novel drug delivery system", 2008, XP055211338, Retrieved from the Internet <URL:http://profdoc.um.ac.ir/articles/a/1009530.pdf> [retrieved on 20150904] *
See also references of WO2011071968A2 *
SEHGAL INDER ET AL: "Photoinduced cytotoxicity and biodistribution of prostate cancer cell-targeted porphyrins", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 51, no. 19, 9 October 2008 (2008-10-09), pages 6014 - 6020, XP009137593, ISSN: 0022-2623, DOI: 10.1021/JM800444C *
VARGAS ANGELICA ET AL: "Toward the understanding of the photodynamic activity of m-THPP encapsulated in PLGA nanoparticles: correlation between nanoparticle properties and in vivo activity", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, vol. 17, no. 8, Suppl, September 2009 (2009-09-01), pages 599 - 609, XP009185401, ISSN: 1061-186X *

Also Published As

Publication number Publication date
EP2509620A2 (en) 2012-10-17
US9211283B2 (en) 2015-12-15
BR112012013952A2 (pt) 2018-06-05
JP5972171B2 (ja) 2016-08-17
CA2784001C (en) 2018-04-10
CA2784001A1 (en) 2011-06-16
WO2011071968A2 (en) 2011-06-16
JP2013513609A (ja) 2013-04-22
US20110142948A1 (en) 2011-06-16
CN102740875A (zh) 2012-10-17
WO2011071968A3 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
EP2509620A4 (en) NANOPARTICLE CARRIER SYSTEM BASED ON HUMAN SERUM ALBUMIN FOR PHOTODYNAMIC THERAPIES
BR112016010564A2 (pt) terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
IL236498A (en) Emergency vehicle patient transport systems
EP2496268A4 (en) GENERATING SYSTEMS ON NANOPARTICLE BASIS
CY1119199T1 (el) Αναστολεις cdc7
ECSP11011441A (es) Compuestos vinil indazolilo
BRPI0908003A2 (pt) sistemas e métodos para o envio de terapia de radiação
ZA201209630B (en) Photodynamic bone stabilization and drug delivery systems
EP2531912A4 (en) SYSTEMS AND METHODS FOR PERSONALLY SUPPORTING HUMAN INTELLIGENCE
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
BR112013014316A2 (pt) tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1
CR20120303A (es) Tratamientos para trastornos gastrointestinales
BR112013010157A2 (pt) inibidores do ibat para o tratamento de doenças do fígado
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
EP2872120A4 (en) TARGETED THERAPEUTIC NANOPARTICLES
BR112015007866A2 (pt) combinação de opióides e fármacos anticancerígenos para o tratamento do câncer.
BRPI1006829A2 (pt) tratamento de um câncer empregando uma combinação de bendamustina e um anticorpo anti-cd20
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
PT2632452T (pt) Compostos e composições para o tratamento do cancro
ES2678498T8 (es) Nanopartículas autoensamblables para la liberación de bisfosfonatos en el tratamiento de cánceres humanos
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
EP2616065A4 (en) GLYCO-SUBSTITUTED DIHYDROXY-CHLORE AND B-FUNCTIONALIZED CHLORE FOR A PHOTODYNAMIC ANTIMICROBIAL THERAPY

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120702

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOLITEC PHARMA IP & INVESTMENT LTD.

A4 Supplementary search report drawn up and despatched

Effective date: 20150918

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20150914BHEP

Ipc: A61K 9/51 20060101ALI20150914BHEP

Ipc: A61K 41/00 20060101ALI20150914BHEP

Ipc: A61K 49/00 20060101ALI20150914BHEP

Ipc: A61K 31/409 20060101ALI20150914BHEP

Ipc: A61P 27/00 20060101ALI20150914BHEP

Ipc: A61K 38/38 20060101AFI20150914BHEP

Ipc: A61K 38/18 20060101ALI20150914BHEP

Ipc: A61K 31/54 20060101ALI20150914BHEP

Ipc: A61P 35/00 20060101ALI20150914BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170602

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038380000

Ipc: A61K0009510000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20241210BHEP

Ipc: A61P 31/04 20060101ALI20241210BHEP

Ipc: A61P 29/00 20060101ALI20241210BHEP

Ipc: A61P 27/02 20060101ALI20241210BHEP

Ipc: A61P 27/00 20060101ALI20241210BHEP

Ipc: A61P 19/02 20060101ALI20241210BHEP

Ipc: A61P 17/00 20060101ALI20241210BHEP

Ipc: A61P 13/00 20060101ALI20241210BHEP

Ipc: A61K 41/00 20060101ALI20241210BHEP

Ipc: A61K 31/409 20060101ALI20241210BHEP

Ipc: A61K 9/51 20060101AFI20241210BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250206

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOLITEC HOLDING GMBH & CO KG

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250729

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3